Bisphosphonate Cancer Risk Divides FDA Officials Ahead Of Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will ask panel whether potential long-term risks of the osteoporosis drugs could be avoided through a "drug holiday."